UNSPSC 51241520: Glycerin/propylene glycol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.

UNSPSC 51241520 Glycerin/propylene glycol is a Commodity code that in recent state and local procurement activity encompasses generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers to government healthcare facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body visible in current activity under this code. MMCAP solicits on behalf of multiple participating state and local government facilities across member states including Oregon. Vendors responding to opportunities under this code must comply with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and FDA requirements; maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) equipped with chargeback systems; and carry comprehensive insurance including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability coverage. Pricing submissions are weighted heavily on competitiveness (75 percent) and must offer flexibility across multiple pricing structures such as flat price, net price formats, or WAC-minus models.

The MMCAP RFP S1070000015802 posted January 20, 2026, with proposals due March 26, 2026, represents the most recent visible opportunity under this code. This multistate cooperative solicits manufacturers to establish two-year contracts (with optional extensions) for generic multi-source pharmaceuticals and OTC products, with awards effective July 1, 2026. Vendors must provide detailed product information including National Drug Codes, SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations, and manufacturing locations; all products must be available in the marketplace by May 15, 2026. The RFP does not disclose specific award values or budget ranges. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations, product availability, patient safety, and member-specific needs, and imposes performance penalties ranging from $200 to $1,500 per violation for issues such as late reporting, missed onboarding, or improper class-of-trade denials.